南京伟思医疗科技股份有限公司 2024年度独立董事述职报告 本人作为南京伟思医疗科技股份有限公司（以下简称"公司"）的独立董 事，2024年度（以下简称"报告期内"），严格按照《中华人民共和国公司 法》《中华人民共和国证券法》《上市公司治理准则》等法律、法规及《公司 章程》《独立董事工作制度》等公司内部规章制度的规定，忠实履行独立董事 的职责，充分发挥独立董事的作用，勤勉尽责，注重维护公司整体利益，维护 全体股东的合法权益。现将报告期内的履职情况报告如下： 一、独立董事基本情况 （一）个人工作履历、专业背景以及兼职情况 吴家璐，男，1978 年出生，中国国籍，无境外永久居留权，博士研究生毕业 于中国协和医科大学临床医学专业。曾任上海市第一人民医院医生、葛兰素史克 （上海）医药研发有限公司医学顾问、默沙东（中国）投资有限公司医学顾问、 启明维创创业投资管理（上海）有限公司副总裁、上海甲辰投资有限公司投资总 监及合伙人、宁波澜芯生物科技有限公司执行董事兼总经理；2015 年 11 月至今， 任广州市金墉基投资管理有限公司监事；2017 年 1 月至 2019 年 6 月，任北京阅 微基因技术股份有限公司董事；20 ...

南京伟思医疗科技股份有限公司 2024年度独立董事述职报告 本人作为南京伟思医疗科技股份有限公司（以下简称"公司"）的独立董 事，2024年度（以下简称"报告期内"），严格按照《中华人民共和国公司 法》《中华人民共和国证券法》《上市公司治理准则》等法律、法规及《公司 章程》《独立董事工作制度》等公司内部规章制度的规定，忠实履行独立董事 的职责，充分发挥独立董事的作用，勤勉尽责，注重维护公司整体利益，维护 全体股东的合法权益。现将报告期内的履职情况报告如下： 一、独立董事基本情况 （一）个人工作履历、专业背景以及兼职情况 肖俊方，男，1966年出生，中国国籍，无境外永久居留权，硕士研究生学 历，高级经济师。2007年11月至2014年1月，任江苏享佳健康管理有限公司董事 长；2007年11月至今，任江苏享佳企业管理有限公司执行董事兼总经理；2011 年9月至今，任南京优品茂电子商务有限公司执行董事；2013年11月至今，任江 苏盛得拍卖有限公司监事；2014年1月至今，任江苏享佳健康科技股份有限公司 董事长；2015年5月至今，任南京老人佳智能科技有限公司董事；2016年1月至 今，任江苏享悦生活科技发展有限公 ...

南京伟思医疗科技股份有限公司 2025 年限制性股票激励计划实施考核管理办法 南京伟思医疗科技股份有限公司 2025 年限制性股票激励计划实施考核管理办法 南京伟思医疗科技股份有限公司（以下简称"公司"或"伟思医疗"）为进一步 完善公司法人治理结构，建立、健全公司长效激励约束机制，吸引和留住公司核 心管理、技术和业务人才，充分调动其积极性和创造性，有效提升核心团队凝聚 力和企业核心竞争力，有效地将股东、公司和核心团队三方利益结合在一起，使 各方共同关注公司的长远发展，确保公司发展战略和经营目标的实现，在充分保 障股东利益的前提下，按照收益与贡献对等的原则，公司制订了《南京伟思医疗 科技股份有限公司 2025 年限制性股票激励计划（草案）》。 为保证公司 2025 年限制性股票激励计划（以下简称"本激励计划"）的顺利实 施，现根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司股权 激励管理办法》《上海证券交易所科创板股票上市规则》《科创板上市公司自律监 管指南第 4 号——股权激励信息披露》等有关法律、行政法规、规范性文件和《公 司章程》的有关规定，并结合公司实际情况，特制订本办法。 第一条 考核目 ...

Financial Performance - The net profit attributable to shareholders for 2024 is RMB 101,969,230.54, with a total distributable profit of RMB 407,359,759.90 as of December 31, 2024[6]. - The company's total revenue for 2024 was CNY 400.06 million, a decrease of 13.45% compared to CNY 462.22 million in 2023[25]. - Net profit attributable to shareholders for 2024 was CNY 101.97 million, down 25.16% from CNY 136.26 million in 2023[25]. - The basic earnings per share for 2024 was CNY 1.0685, reflecting a decline of 25.07% from CNY 1.4260 in 2023[26]. - The cash flow from operating activities for 2024 was CNY 118.29 million, down 11.86% from CNY 134.20 million in 2023[25]. - The company's total assets at the end of 2024 were CNY 1,820.36 million, an increase of 0.79% from CNY 1,806.02 million at the end of 2023[25]. - The net assets attributable to shareholders at the end of 2024 were CNY 1,627.46 million, showing a slight increase of 0.04% from CNY 1,626.76 million in 2023[25]. - The company's total revenue for 2024 was 395.34 million, a decrease of 13.20% compared to the previous year[139]. - The gross profit margin for the overall business was 65.08%, reflecting a decrease of 2.24 percentage points compared to the previous year[137]. Dividend Distribution - The company plans to distribute a cash dividend of RMB 8 per 10 shares, totaling approximately RMB 76,569,346.40, which represents 88.45% of the net profit for the year[8]. - No capital reserve fund will be converted into share capital, and no bonus shares will be issued, with remaining undistributed profits carried forward[8]. Research and Development - Research and development expenses accounted for 16.45% of total revenue in 2024, a decrease of 0.52 percentage points from 16.97% in 2023[26]. - The company obtained 17 new patents during the reporting period, including 10 invention patents, bringing the total to 255 authorized patents[38]. - Total R&D expenditure decreased by 16.10% year-on-year, amounting to ¥65,802,296.31[108]. - The company has established six major technology platforms, including magnetic stimulation and laser technology, enhancing its core competitive advantage[118]. - The company is committed to continuous innovation and product development, aiming to align with global benchmarks and drive the advancement of rehabilitation technology[175]. Product Development and Innovation - The company focuses on rehabilitation technologies for postpartum conditions such as urinary incontinence and pelvic pain[15]. - The company has developed a neuromuscular electrical stimulation technology aimed at functional recovery through targeted muscle stimulation[15]. - The company is engaged in research and development of transcranial magnetic stimulation (TMS) technology for cognitive and motor function improvement[16]. - The company launched the MagNeuro ONE series transcranial magnetic stimulation device, enhancing its competitive advantage in the mental rehabilitation equipment sector[38]. - The company has developed a miniaturized high-pressure medical power supply for magnetic stimulation products, meeting output requirements of 150Hz pulse frequency and 6 Tesla magnetic field strength[97]. Market Expansion and Strategy - The company is actively pursuing international market expansion, seeking strategic partnerships with global collaborators to build a cross-border academic promotion network[54]. - The company plans to expand its market share in rehabilitation by enhancing its product matrix in postpartum recovery, psychological rehabilitation, and pediatric rehabilitation[37]. - The marketing strategy includes expanding into grassroots and private medical markets, optimizing the sales network, and increasing market penetration in gynecology and urology departments, aiming for new sales breakthroughs[180]. Corporate Governance - The company held 2 shareholder meetings during the reporting period, complying with relevant laws and regulations[189]. - A total of 6 board meetings were conducted, with independent directors attending and providing independent opinions[190]. - The independent directors actively participated in board discussions and decision-making on significant matters[192]. - The company approved 15 resolutions at the shareholder meetings, including the 2023 annual financial budget and profit distribution plan[193]. Risk Management - The company has detailed various risks and countermeasures in its annual report[3]. - The company is focusing on ensuring that product development aligns with market demand to address potential risks in technology and product competitiveness[127]. - The company is actively monitoring industry policies and regulations to adapt its strategies accordingly, minimizing risks from regulatory changes[131]. Customer Engagement and Satisfaction - Customer satisfaction ratings improved to 90%, reflecting a 5% increase from the last quarter[200]. - The company is focusing on improving user engagement through the optimization of its smart cloud products, reducing maintenance costs and enhancing operational efficiency[114]. Employee Incentives and Retention - The company has implemented a multi-layered incentive mechanism, aligning employee contributions with corporate value growth[126]. - The overall increase in shares and stock incentives indicates a positive outlook for employee engagement and future growth potential[197].

Financial Performance - The company's operating revenue for Q1 2025 was CNY 95,912,701.63, representing a year-on-year increase of 9.40% compared to CNY 87,670,336.46 in the same period last year[4] - Net profit attributable to shareholders for the same period was CNY 33,220,075.05, a significant increase of 52.71% from CNY 21,753,153.33 in the previous year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 30,538,332.03, reflecting a year-on-year growth of 58.96%[4] - Basic earnings per share for the period were CNY 0.3472, up 52.08% from CNY 0.2283 in the same period last year[4] - Total operating revenue for Q1 2025 reached ¥95,912,701.63, an increase of 9.3% compared to ¥87,670,336.46 in Q1 2024[17] - Net profit for Q1 2025 was ¥33,220,075.05, representing a significant increase of 52.9% from ¥21,753,153.33 in Q1 2024[18] - Earnings per share (EPS) for Q1 2025 was ¥0.3472, compared to ¥0.2283 in Q1 2024, reflecting a growth of 52.2%[19] - The total comprehensive income for Q1 2025 was ¥33,220,075.05, up from ¥21,753,153.33 in Q1 2024[19] Cash Flow - The net cash flow from operating activities reached CNY 22,402,640.36, marking a substantial increase of 138.68% compared to CNY 9,386,067.11 in the previous year[4] - Cash flow from operating activities generated a net amount of ¥22,402,640.36, a substantial increase from ¥9,386,067.11 in the previous year[22] - Cash inflow from investment activities totaled ¥794,277,213.51, compared to ¥275,133,776.46 in Q1 2024[22] - Cash outflow from investment activities was ¥825,866,799.39, leading to a net cash flow from investment activities of -¥31,589,585.88[22] - The beginning cash and cash equivalents balance was $1,067,206,832.73, compared to $1,153,801,027.71 in the previous period[23] - The ending cash and cash equivalents balance was $1,058,019,311.52, down from $1,112,314,830.54 in the previous period[23] Research and Development - Total R&D expenditure was CNY 12,238,776.10, which is a decrease of 35.08% compared to CNY 18,851,562.73 in the previous year[4] - The proportion of R&D expenditure to operating revenue decreased to 12.76%, down 8.74 percentage points from 21.50% in the previous year[5] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,815,959,275.03, a slight decrease of 0.24% from CNY 1,820,364,713.20 at the end of the previous year[5] - The company's current assets totaled ¥1,155,426,317.71, down from ¥1,163,272,383.49 at the end of 2024, indicating a decrease of approximately 0.9%[14] - Cash and cash equivalents were reported at ¥1,059,037,112.46, a decrease from ¥1,068,159,804.95, reflecting a decline of about 0.1%[13] - Accounts receivable decreased to ¥23,388,812.25 from ¥25,152,299.37, representing a decline of approximately 7%[13] - Inventory decreased to ¥36,298,586.40 from ¥38,737,651.18, indicating a reduction of about 6.3%[14] - Total liabilities decreased to ¥153,858,172.25 from ¥192,901,823.87, showing a significant reduction of approximately 20.3%[15] - The company's equity capital remained stable at ¥95,771,288.00, unchanged from the previous period[15] - The company reported a decrease in accounts payable from ¥19,404,406.21 to ¥14,466,093.63, a decline of about 25.5%[15] - The total non-current assets increased slightly to ¥660,532,957.32 from ¥657,092,329.71, reflecting a growth of approximately 0.7%[14] - The company's total equity attributable to shareholders reached ¥1,662,101,102.78, an increase from ¥1,627,462,889.33 year-over-year[16] - The total liabilities and equity amounted to ¥1,815,959,275.03, slightly down from ¥1,820,364,713.20 in the previous year[16] Shareholder Information - The company reported a total of 5,933 common shareholders at the end of the reporting period[10] - The company has not reported any significant changes in shareholder relationships or actions during the reporting period[12] Accounting Standards - The company will not apply the new accounting standards or interpretations starting from 2025[23]

南京伟思医疗科技股份有限公司 经核查独立董事肖俊方、蔡卫华、吴家璐的任职情况以及签署的相关自查文 件，上述人员未在公司担任除独立董事及董事会各相关专门委员会成员以外的任 何职务，也未在公司主要股东公司担任任何职务，与公司以及主要股东之间不存 在利害关系、重大业务往来或其他可能妨碍其进行独立客观判断的关系。因此， 董事会认为公司独立董事符合《上市公司独立董事管理办法》《上海证券交易所 科创板上市公司自律监管指引第 1 号——规范运作》中对独立董事独立性的相关 要求。 南京伟思医疗科技股份有限公司董事会 2025 年 4 月 24 日 董事会对独立董事独立性自查情况的专项报告 根据中国证券监督管理委员会《上市公司独立董事管理办法》《上海证券交 易所科创板上市公司自律监管指引第 1 号——规范运作》等要求，南京伟思医疗 科技股份有限公司（以下简称"公司"）董事会就公司 2024 年度末在任独立董事 肖俊方、蔡卫华、吴家璐的独立性情况进行评估并出具如下专项意见： ...

证券代码：688580 证券简称：伟思医疗 公告编号：2025-011 南京伟思医疗科技股份有限公司 关于续聘会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 拟续聘的会计师事务所名称：天衡会计师事务所（特殊普通合伙） 本事项尚需提交南京伟思医疗科技股份有限公司（以下简称"伟思医疗" 或"公司"）股东大会审议。 一、拟聘任会计师事务所的基本情况 （一）机构信息 1、基本信息 事务所名称：天衡会计师事务所（特殊普通合伙） 成立日期：2013 年 11 月 4 日 组织形式：特殊普通合伙企业 历史沿革：天衡会计师事务所（特殊普通合伙）前身为始建于 1985 年的江 苏会计师事务所，1999 年脱钩改制，2013 年转制为特殊普通合伙会计师事务所。 首席合伙人：郭澳 | | | | 2024 年度末合伙人数量 | 85 | | --- | --- | --- | --- | --- | | 2024 | 年 | 度 | | | | 末人员数量（单 位：人） | | | 2024 年度末注册会计师 ...

根据《中华人民共和国公司法》《中华人民共和国证券法》《国有企业、上市公司选 聘会计师事务所管理办法》《上海证券交易所科创板股票上市规则》《上海证券交易所科 创板上市公司自律监管指引第 1 号——规范运作》等法律法规的要求，南京伟思医疗科 技股份有限公司（以下简称 "公司"）董事会审计委员会对天衡会计师事务所（特殊普 通合伙）审计资质及 2024 年度审计工作履行了监督职责，现将相关情况报告如下： 一、2024 年年审会计师事务所基本情况 （一）机构信息 南京伟思医疗科技股份有限公司 董事会审计委员会对会计师事务所 2024 年度履行监 督职责情况报告 1.基本信息 事务所名称：天衡会计师事务所（特殊普通合伙） | 2024 年度末 | 2024 | 年度末合伙人数量 | 85 | | --- | --- | --- | --- | | 人员数量（单位： | 2024 | 年度末注册会计师人数 | 386 | | 人） | 2024 | 年度末签署过证券服务业务审 | 227 | | | | 计报告的注册会计师人数 | | | 2024 年度业 | 2024 | 年度经审计的收入总额 | 52,937.55 | ...

内部控制审计报告 天衡专字(2025)00559 号 南京伟思医疗科技股份有限公司 2024 年度内部控制审计报告 【天衡专字(2025)00559 号】 天衡会计师事务所（特殊普通合伙） ，您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.gov.cn）"进行的 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.gov.cn）"进行的 1 t with a 南京伟思医疗科技股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我们审计了 南京伟思医疗科技股份有限公司 2024 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评价指引》 的规定,建立健全和有效实施内部控制,并评价其有效性是南京伟思医疗科技股份有限公司 董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上,对财务报告内部控制的有效性发表审计意见, 并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 ...

证券代码：688580 证券简称：伟思医疗 公告编号：2025-013 南京伟思医疗科技股份有限公司 关于使用部分暂时闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 南京伟思医疗科技股份有限公司(以下简称"公司"或"伟思医疗")于 2025 年 4 月 24 日召开第四届董事会第三次会议、第四届监事会第三次会议审议通过了 《关于使用部分暂时闲置募集资金进行现金管理的议案》,同意公司在确保不影响 募集资金投资项目建设和使用的情况下，使用最高不超过人民币 8,000 万元的暂时 闲置募集资金进行现金管理，购买安全性高、流动性好、具有合法经营资格的金融 机构销售的有保本约定的理财产品（包括但不限于保本型理财产品、结构性存款、 定期存款、通知存款、大额存单等）。上述额度自公司董事会审议通过之日起 12 个月内有效，在决议有效期内，资金可以滚动使用，并于到期后归还至募集资金专 项账户。同时，董事会授权董事长在额度范围内行使投资决策权并签署相关法律文 件，包括但不限于选择合格的理财产品发行主体、明确理财 ...